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PD123319 Augments Angiotensin II-Induced Abdominal
Aortic Aneurysms through an AT2 Receptor-Independent
Mechanism
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Abstract
Background: AT2 receptors have an unclear function on development of abdominal aortic aneurysms (AAAs), although a
pharmacological approach using the AT2 receptor antagonist PD123319 has implicated a role. The purpose of the present
study was to determine the role of AT2 receptors in AngII-induced AAAs using a combination of genetic and
pharmacological approaches. We also defined effects of AT2 receptors in AngII-induced atherosclerosis and thoracic aortic
aneurysms.
Methods and Results: Male AT2 receptor wild type (AT2 +/y) and deficient (AT2 -/y) mice in an LDL receptor 2/2
background were fed a saturated-fat enriched diet, and infused with either saline or AngII (500 ng/kg/min). AT2 receptor
deficiency had no significant effect on systolic blood pressure during AngII-infusion. While AngII infusion induced AAAs, AT2
receptor deficiency did not significantly affect either maximal width of the suprarenal aorta or incidence of AAAs. The AT2
receptor antagonist PD123319 (3 mg/kg/day) and AngII were co-infused into male LDL receptor 2/2 mice that were either
AT2 +/y or 2/y. PD123319 had no significant effect on systolic blood pressure in either wild type or AT2 receptor deficient
mice. Consistent with our previous findings, PD123319 increased AngII-induced AAAs. However, this effect of PD123319
occurred irrespective of AT2 receptor genotype. Neither AT2 receptor deficiency nor PD123319 had any significant effect on
AngII-induced thoracic aortic aneurysms or atherosclerosis.
Conclusions: AT2 receptor deficiency does not affect AngII-induced AAAs, thoracic aortic aneurysms and atherosclerosis.
PD123319 augments AngII-induced AAAs through an AT2 receptor-independent mechanism.
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Introduction
Chronic infusion of angiotensin II (AngII) into hypercholester-
olemic mice promotes formation of aortic aneurysms that
predominantly localize to the suprarenal aortic (AAAs) and
ascending aortic (TAAs) regions and augments atherosclerotic
lesions [1–4]. AngII exerts its bioactive effects through binding to
AT1 and AT2 receptors. In rodents, AT1 receptors are expressed
as two subtypes termed AT1a and AT1b. AT1a receptors are the
most predominant AngII receptor subtype in many tissues of adult
mice, whereas AT2 receptors are abundant in fetal development
with expression restricted to adrenal glands, brain, kidneys, and
heart of adult rodents [5]. The AT2 receptor gene is located on the
X chromosome. AngII-induced aortic aneurysms and atheroscle-
rosis are diminished by administration of an AT1 receptor
antagonist, losartan, or in mice with AT1a receptor deficiency
[4,6,7], demonstrating a critical role of AngII-AT1a receptor
interaction on aortic pathologies. Despite its low expression in
many tissues of adult rodents, AT2 receptors are upregulated
during vascular injury [8]. Furthermore, vascular responses to
AngII in the absence of AT2 receptors are increased, which are
accompanied by upregulation of AT1 receptors [9,10]. Therefore,
it has been proposed that the AngII-AT2 receptor interaction
opposes effects of AngII through AT1 receptor activation.
Previous studies have determined roles for AT2 receptors on
aortic aneurysms and atherosclerosis using either pharmacological
or genetic approaches [6,11–16]. Pharmacological assessments of
AT2 receptors in vivo have been limited to the use of a single
antagonist, PD123319. While we have reported that PD123319
augments AngII-induced AAAs [6], there are conflicting findings
regarding the effects of PD123319 on atherosclerosis. These range
from attenuating atherosclerosis in diabetic apolipoprotein (apoE)
2/2 mice [15], having no effect on AngII-induced atherosclerosis
in apoE 2/2 mice [6,12], to increased atherosclerosis in young
apoE 2/2 female mice [6] or apoE and AT1a receptor double
deficient mice [16]. Since there is always potential for a drug to
exert effects through an ancillary effect beyond its class-specific
property, it is unclear whether these inconsistencies are due to off-
target effects of PD123319. AT2 receptor deficient mice were
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developed by two independent groups [17,18]. In agreement with
the inconsistent results from PD123319, AT2 receptor deficiency
has shown reduction [15], augmentation [13,14], no effect [11], or
no effect on lesion size but influencing cellular and molecular
elements in atherosclerotic lesions [14]. No study has determined
the role of genetic AT2 receptor deficiency on AngII-induced
aortic aneurysms.
In the present study, we defined the role of AT2 receptor
deficiency on AngII-induced aortic aneurysms and atherosclerosis.
We also infused PD123319 into wild type and AT2 receptor
deficient mice to define the specificity of this pharmacological
approach on these aortic pathologies.
Materials and Methods
Ethics Statement
All mouse studies were performed with approval of the
University of Kentucky Institutional Animal Care and Use
Committee.
Mice and Diets
LDL receptor 2/2 mice of C57BL/6 background were
purchased from the Jackson Laboratory (B6.129S7-Ldlrtm1Her;
Stock # 002207; Bar Harbor, ME). Male AT2 receptor deficient
mice were supplied by Dr. Inagami at Vanderbilt University.
Since AT2 receptor is located on the X chromosome, male AT2
receptor deficient mice are represented as AT2 -/y, and wild type
littermates are denoted as AT2 +/y. Male AT2 -/y mice and
female LDL receptor 2/2 mice were mated, and their offspring
were bred to generate LDL receptor 2/2 mice that were either
wild type or deficient for AT2 receptors. Only male mice were
used in this study since females are not susceptible to AngII-
induced AAAs [19]. All mice were maintained in a barrier facility
and fed a normal rodent diet ad libitum.
To induce hypercholesterolemia, mice were fed a diet
supplemented with saturated fat (milk fat 21% wt/wt; Diet #
TD.88137; Harlan Teklad; Indianapolis, IN). This diet feeding
started 1 week prior to pump implantation and was maintained
during 4 weeks of infusion. The entire duration of fat-enriched diet
feeding was 5 weeks.
Genotyping and Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
AT2 receptor genotypes of mice were confirmed using PCR.
AT2 receptor genotyping used the following primers: forward
59-GTAAGAATTTGGAGTTGCTG, and reverse 59-GGGAT-
TCCTTCTTTGAGAC. PCR reaction was 35 cycles of 95uC for
1 min, 56uC for 1 min, and 72uC for 2 min; and 1 cycle of 72uC
for 5 min. Resultant amplicons for wild type and disrupted alleles
were 500 bp and ,1.1 kb, respectively as shown in Figure S1A.
LDL receptor genotyping used the following primers: 59-
AGGTGAGATGACAGGAGATC, 59-AGGATGACTTCC-
GATGCCAG, and 59-GCAGTGCTCCTCATCTGACTTG.
PCR reaction was 35 cycles of 95uC for 1 min, 50uC for 1 min,
and 72uC for 2 min; and 1 cycle of 72uC for 5 min as described
previously.
RNA was isolated from aortic tissues of LDL receptor 2/2
mice, that were either AT2 +/y or 2/y, using the SV Total RNA
Isolation System (Catalog # Z3100, Promega Corp, Madison,
MI). RT-PCR of AT2 receptor and b-actin was performed using
the Access RT-PCR system (Catalog # A1250, Promega Corp) in
a thermocycler (Bio-Rad, Hercules, CA, USA) as described
previously. Samples containing either no template or no RT
reactions were used as negative controls.
Osmotic Minipump Implantation and AngII Infusion
Osmotic minipumps (Alzet Model 2004; Durect Corp; Cuper-
tino, CA) were implanted subcutaneously to deliver saline, AngII
(500 ng/kg/min; catalog # A9525; Sigma-Aldrich; St. Louis,
MO), or PD123319 (3 mg/kg/d; catalog # P186, Sigma-Aldrich)
as described previously [1,6].
Serum Cholesterol Measurement
Serum cholesterol concentrations were determined using
commercially available enzymatic assay kits (Catalog # 439-
17501; Wako Chemicals; Richmond, VA). Lipoprotein cholesterol
distributions were performed by size exclusion chromatography as
described previously [20].
Systolic Blood Pressure Measurement
Systolic blood pressures were measured on conscious, restrained
mice using a non-invasive tail cuff system (BP-2000; Visitech;
Apex, NC) at the same time of each day, 5 consecutive days every
week as described previously [21].
Aortic Aneurysm and Atherosclerosis Quantification
Aortas were excised at termination and fixed with 10%
neutrally buffered formalin. After cleaning off adventitia, maximal
aortic widths of suprarenal aortas were quantified by measuring ex
vivo maximal diameters of suprarenal aortas using an Image-Pro
Plus software (Media Cybernetics; Rockville, MD) as described
previously [22]. Definition of AAA incidence included those
having ex vivo aortic width at least 50% larger compared to the
mean aortic width measured in mice infused with saline as well as
death due to aortic rupture located in abdominal aortas.
Atherosclerosis was quantified on intima of the aortic arch
region that contained the ascending portion, arch, and part of the
descending thoracic portion (from the aortic orifice of left
subclavian artery to 3 mm below) as described previously [23–25].
Characterization of Abdominal Aortic Aneurysms
Three suprarenal aortas from each group were chosen based on
the mean maximal diameter as shown in Figure S2, embedded in
OCT, and serially sectioned using a cryostat. The aneurysm was
sectioned (10 mm of thickness) in serial sets consisting of 10 slides
with 10 serial sections per slide as described previously [26].
Movat’s pentachrome staining was performed using a commercial
kit (Catalog # K042; Poly Scientific R & D Corp; Bay Shore, NY)
to distinguish elastin fibers and collagen in AAA tissues.
Statistical Analyses
Version 9.2 of SAS (SAS Institute Inc.; Cary, NC) and
SigmaStat (Point Richmond, CA) were used for statistical analyses.
Data are represented as mean6standard error of the mean (SEM).
Two way ANOVA was performed to compare continuous
variables among groups that contained factors including two
genotypes (AT2 +/y versus AT2 -/y) and two manipulations
(saline versus AngII, or AngII versus AngII+PD123319). Incidence
of AAAs was analyzed using Fisher’s exact test. Systolic blood
pressure data were analyzed using two way repeated measures
ANOVA. P,0.05 was considered significant.
Results
AT2 Receptor Deficiency Did Not Change Aortic
Pathologies in Mice Infused with AngII
Presence or deletion of AT2 receptors in mice was confirmed by
AT2 receptor genotyping (Figure S1A) and RT-PCR showing a
AT2 Receptors and Aortic Pathologies
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complete absence of AT2 receptor mRNA in aortic tissues (Figure
S1B). Infusion of either saline or AngII (500 ng/kg/min) had no
significant effect on systolic blood pressure in either AT2 +/y or
AT2 -/y mice (Table 1). A small, but significant, effect of genotype
on body weights was detected (AT2 +/y versus AT2 -/y: P = 0.03
in Table 1), but there was no significant effect for manipulation
(saline versus AngII infusion) or interaction between AT2 receptor
genotype and manipulation. Plasma cholesterol concentrations
showed a small but significant difference between AT2 +/y and
AT2 -/y mice infused with AngII (P = 0.001; Table 1), whereas
there was no significant difference between the two AT2 genotypes
infused with saline.
Consistent with our previous findings [1,6], infusion of AngII
led to significant increases in maximal widths of suprarenal aortas
(Figure 1) and incidence of AAAs (saline versus AngII: 0% versus
40%; P = 0.004). AT2 receptor deficiency had no significant effect
on AngII-induced AAAs, as determined by both maximal widths
of suprarenal aortas (Figure 1) and incidence of AAAs (AT2 +/y
versus 2/y: 40% versus 28%; P = 0.74). Death due to aortic
rupture occurred in 1 of 17 AT2 +/y mice, and in 0 of 18 AT2 2/
y mice.
In addition to AngII infusion inducing AAAs, we have reported
previously that AngII infusion induced TAAs localized to the
ascending portion of thoracic aortas and augmented hypercholes-
terolemia-induced atherosclerosis [1,3,4]. Consistent with the
previous reports, AngII infusion induced TAAs as defined by
increased intimal area of the aortic arch (Figure 2) and augmented
atherosclerosis in the same region (Figure 3). However, AT2
receptor deficiency had no significant effect on either of these
AngII-induced aortic pathologies.
PD123319 Augmented AngII-induced AAAs Independent
of AT2 Receptor Genotype
PD123319 is the most commonly used AT2 receptor antagonist
to define AT2 receptor effects in vitro and in vivo. As shown in our
previous study, PD123319 augmented AngII-induced AAAs [6].
However, while this compound exerts specificity for AT2 receptors
in vitro [27,28], no studies have defined the in vivo specificity of
PD123319 by administering the antagonist to AT2 receptor
deficient mice. Therefore, we co-infused AngII and PD123319
into male LDL receptor 2/2 mice that were either AT2 +/y or
2/y. Co-infusion of PD123319 with AngII did not significantly
change body weights, plasma cholesterol concentrations, or
systolic blood pressures in either AT2 +/y or 2/y mice
(Table 2). However, co-infusion of PD123319 with AngII
increased AAAs as demonstrated by both maximal widths of
suprarenal aortas and incidence of AAAs, irrespective of AT2
genotype (Figure 4 and Figure S2). There was no significant effect
of PD123319 on AngII-induced TAAs (Figure 5) or atherosclerosis
(Figure 6) in either AT2 genotype. Rate of death due to aortic
rupture in the abdominal region was not significantly different by
either AT2 receptor genotype or manipulation (Table 2).
Infusion of AngII at a rate of 500 ng/kg/min promoted limited
pathology with minimal disruption of elastin fibers (Figure S3). In
contrast, administration of PD123319 greatly enhanced aortic
pathology with appearance of transmural elastin breaks of aortic
media and aberrant collagen accumulation. Marked heterogeneity
of cellular characteristics in AngII-induced AAAs was also evident
in mice administered PD123319. We were unable to discern any
differences in cellular characteristics of aneurysmal tissues in mice
administered PD123319 irrespective of AT2 receptor genotype.
Discussion
This study, using both genetic disruption and pharmacological
inhibition approaches, demonstrated that AT2 receptor deficiency
did not influence AngII-induced AAAs, TAAs, and atherosclerosis
in hypercholesterolemic mice. Notably, while PD123319 aug-
mented AngII-induced AAAs in AT2 receptor wild type mice, the
drug was equally effective in promoting this effect in AT2 receptor
deficient mice. This infers that when administered in vivo,
Table 1. Characteristics of Mice Infused with either Saline or AngII.
Infusion AT2 Genotype N Body Weight (g) Plasma Cholesterol (mg/dl) Systolic Blood Pressure (mmHg)
Saline +/y 11 29.761.1 1438661 13865
2/y 11 32.461.2 * 1444637 13663
Ang II +/y 16 29.860.4 1330635 14464
2/y 18 30.960.8 * 1590658 # 13963
Body weights and plasma cholesterol concentrations were determined at termination. Systolic blood pressures were recorded during the last week of the study. Values
are represented as mean6SEM. Two way ANOVA was performed for body weights and plasma cholesterol concentrations, and two way repeated measures ANOVA was
used to analyze systolic blood pressures. * P = 0.03 between AT2 +/y and 2/y genotypes. # P = 0.001 between AT2 +/y and 2/y mice infused with AngII. There were no
significant differences between AT2 receptor genotypes (+/y versus 2/y) and between manipulations (saline versus AngII) for systolic blood pressures.
doi:10.1371/journal.pone.0061849.t001
Figure 1. AT2 receptor deficiency did not change suprarenal
aortic expansion in mice infused with AngII. Maximal aortic width
of suprarenal aortas was measured ex vivo. Circles and inverted
triangles represent values from individual mice, diamonds are mean
values of each group, and bars are SEM. * P = 0.002 between AngII-
infused groups and saline-infused groups as analyzed by two way
ANOVA. There were no significant effects of genotype (AT2 +/y versus
AT2 2/y) on aortic width.
doi:10.1371/journal.pone.0061849.g001
AT2 Receptors and Aortic Pathologies
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PD123319 exerts its effects through a mechanism that is
independent of AT2 receptor antagonism.
There is compelling evidence from many laboratories that
AngII infusion promotes aortic aneurysms and augments athero-
sclerosis [1,3,4,29–32]. Among the 3 subtypes of AngII receptors
in rodents, AT1a receptors promote AngII-induced aortic
aneurysms and atherosclerosis as demonstrated by pharmacolog-
ical inhibition of AT1 receptors [6] and genetic deletion of AT1a
receptors [4,7] in our previous studies. In contrast to the well-
defined functional effects of the AngII-AT1a receptor interaction,
no study has employed both pharmacological and genetic
approaches to defining effects of AT2 receptors on AngII-induced
AAAs. Definition of AT2 receptor function in vivo has been
limited by the availability of few pharmacological tools. The most
commonly used pharmacological reagents are PD123319 as an
antagonist and CGP42112 as a partial agonist, respectively. We
reported previously that simultaneous administration of
PD123319 at the same dose (3 mg/kg/day) used in the present
study with AngII infusion into hypercholesterolemic mice exacer-
bated AAAs [6]. A range of doses (1–50 mg/kg/day) of PD123319
were used to define several different AT2 receptor-dependent
effects in mice [28,33–36]. The dose of PD123319 (3 mg/kg/day)
used in the present study was similar to the lowest dose used in
most mouse studies [6,12], which minimize the possibility of
nonspecific effects of this compound. Despite this low dose, AT2
receptor independent effects of PD123319 on AAAs, but not on
atherosclerosis and systolic blood pressure, were demonstrated in
AngII-infused mice lacking AT2 receptors. There are also reports
that 5 mg/kg/d of PD123319 decreased atherosclerosis in diabetic
apoE 2/2 mice [15], while 30 mg/kg/d of PD123319 did not
affect systolic blood pressure in C57BL/6 mice infused with AngII
500 ng/kg/min [37]. These findings indicate that there might be
Figure 2. AT2 receptor deficiency did not change expansion of
the aortic arch region in mice infused with AngII. Intimal area of
aortic arches was calculated from en face measurements. Circles and
inverted triangles represent values from individual mice, diamonds are
mean values of each group, and bars are SEM. * P = 0.0003 between
AngII-infused and saline-infused groups as analyzed by two way
ANOVA. There were no significant effects of genotype (AT2 +/y versus
AT2 2/y) on intimal areas of aortic arches.
doi:10.1371/journal.pone.0061849.g002
Figure 3. AT2 receptor deficiency did not change percent
atherosclerotic lesion area in mice infused with AngII. Percent
atherosclerotic lesion area of aortic arches was calculated as lesion area/
intimal surface area (x 100%). Circles and inverted triangles represent
values from individual mice, diamonds are mean values of each group,
and bars are SEM. * P,0.0001 between AngII-infused groups and saline-
infused groups as analyzed by two way ANOVA. There were no
significant effects of genotype (AT2 +/y versus AT2 2/y) on lesion areas.
doi:10.1371/journal.pone.0061849.g003
Figure 4. PD123319 augmented AngII-induced suprarenal
aortic expansion and incidence of AAAs independent of AT2
receptor genotype. A. Maximal aortic width of suprarenal aortas was
measured ex vivo. Circles and inverted triangles represent values from
individual mice, diamonds are mean values of each group, and bars are
SEM. * P = 0.01 between AngII-infused and PD123319-infused groups as
analyzed by two way ANOVA. There were no significant effects on aortic
width for genotypes (AT2 +/y versus AT2 2/y). B. Incidence of AAAs. *
P = 0.006 between AngII-infused and PD123319-infused groups as
analyzed by Fisher’s Exact test. There were no significant effects of
genotype (AT2 +/y versus AT2 2/y) on incidence of AAAs.
doi:10.1371/journal.pone.0061849.g004
AT2 Receptors and Aortic Pathologies
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dose-dependent responses for off-target effects of PD123319 on
different parameters.
The ablation effect of AT1a receptor deficiency on AngII-
induced AAAs and augmentation of this aortic pathology by
PD123319 implied that AT2 receptors may antagonize AT1a
receptor-mediated pathophysiological roles of AngII. Given
previous findings [6], these results prompted us to test whether
PD123319 increases AAAs through an AT2 receptor-dependent
mechanism. Consistent with our previous study [6], co-infusion of
PD123319 with AngII led to augmentation of AAAs. Additionally,
as demonstrated by Movat’s pentachrome staining, PD123319
administration led to severe destruction of the aortic wall.
However, this effect was comparable between the two AT2
genotypes, inferring that PD123319 augmented AngII-induced
AAAs through an ancillary mechanism that is independent of
AngII-AT2 receptor interaction. To support the findings from the
present study, a previous study has provided evidence that
PD123319 acts through an AT2 receptor-independent mechanism
in AngII-induced vasoconstriction in mice [38]. Although
PD123319 significantly increased AngII-induced AAAs indepen-
dent of AT2 receptors, the complexity of the aneurysmal response
will provide a challenge in determining the mechanism of this
effect [36,39,40].
In addition to AAAs and atherosclerosis, chronic AngII induces
TAAs that are restricted to the ascending aortic region [3,4]. The
role of AngII receptors has also been inferred in another mouse
model with TAAs that is provoked by mutation of fibrillin-1
[41,42]. Losartan, an AT1 receptor antagonist, reduced TAAs in
this mouse model with Marfan syndrome [41], whereas AT2
receptor deficiency augmented aortic expansion in this mouse
model [42]. These findings indicate that AT2 receptors may
prevent aortic expansion through antagonizing AngII-AT1
activation. For comparison to these reports, we also defined the
role of AT2 receptors on AngII-induced TAAs in the present
study. As noted previously, AngII infusion induced TAAs in LDL
receptor 2/2 mice irrespective of AT2 genotype. In contrast to
AngII-induced AAAs, neither AT2 receptor deficiency nor
Figure 5. PD123319 did not change AngII-induced expansion
of the aortic arch region. Intimal area of aortic arches was measured
using an en face method after termination. Circles and inverted
triangles represent values from individual mice, diamonds are mean
values of each group, and bars are SEM. There were no significant
effects of genotype (AT2 +/y versus AT2 -/y) or PD123319 on intimal
areas of the aortic arch region, as demonstrated by two way ANOVA.
doi:10.1371/journal.pone.0061849.g005
Figure 6. PD123319 did not change atherosclerotic lesion size
in mice infused with AngII. Percent atherosclerotic lesion area of
aortic arches was calculated as lesion area/intimal surface area (x 100%).
Circles and inverted triangles represent values from individual mice,
diamonds are mean values of each group, and bars are SEM. There were
no significant effects of genotype (AT2 +/y versus AT2 2/y) or
PD123319 on lesion areas, as demonstrated by two way ANOVA.
doi:10.1371/journal.pone.0061849.g006
Table 2. Characteristics of Mice Infused with AngII alone or both AngII and PD123319.
Infusion AT2 Genotype N Body Weight (g)
Plasma Cholesterol
(mg/dl)
Systolic Blood Pressure
(mmHg) Aortic Rupture
AngII +/y 11 29.861.2 1062644 15465 0/11
2/y 11 29.561.5 1029683 16067 2/9
Ang II+PD123319 +/y 8 28.360.6 1028637 15267 3/10
2/y 7 26.860.9 11516167 15566 3/10
Body weights and plasma cholesterol concentrations were determined at termination. Systolic blood pressures were recorded during the last week of the study. Aortic
rupture was confirmed by necropsy with visible blood clot in the abdominal cavity and verification of disrupted aortic structure of abdominal aorta. Values are
represented as mean6SEM. Two way ANOVA was performed for body weights and plasma cholesterol concentrations, two way repeated measures ANOVA was used to
analyze systolic BP data, and Fisher’s exact test was done for aortic rupture rate. There were no significant differences between AT2 receptor genotypes (+/y versus 2/y)
and between manipulations (AngII versus AngII+PD123319) for all parameters tested in this table.
doi:10.1371/journal.pone.0061849.t002
AT2 Receptors and Aortic Pathologies
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PD123319 significantly affected AngII-induced TAAs. Therefore,
unlike TAAs associated with fibrillin-1 mutations [42], our results
do not support a role of AT2 receptors in AngII-induced TAAs.
In the current study, the role of AT2 receptors on AngII-
induced atherosclerosis was determined in male LDL receptor 2/
2 mice. AT2 receptor deficiency and PD123319 administration
have been used in several studies in apoE 2/2 mice to determine
effects on atherosclerosis with variable results [12–15,34]. In the
current study, neither deficiency of AT2 receptors nor PD123319
administration (separately or concomitantly) had any effect on
atherosclerotic lesion size. Therefore, this study provides further
confirmation for a limited role of AT2 receptors in atherosclerosis.
In conclusion, AT2 receptor deficiency has no effect on either
aortic aneurysms or atherosclerosis. PD123319, despite being
accepted as a specific AT2 antagonist, augments AngII-induced
AAAs through an AT2 receptor-independent mechanism.
Supporting Information
Figure S1 Verification of AT2 receptor deficiency in AT2
-/y mice. (A) Genotypes of the AT2 receptor were determined
with PCR. Primers (arrows in cyan color) were located upstream
and downstream of the neo sequence in exon 3 of the AT2
receptor gene, respectively. Amplicon sizes of wild type and
disrupted alleles were 500 bp and , 1100 bp, respectively. (B)
mRNA of AT2 receptor (160 bp) and b-actin (236 bp) was
determined by RT-PCR. AT2 receptor mRNA was detectable in
extracts of aortas from AT2 +/y mice, but not from AT2 -/y mice.
No RT was used as a negative control.
(PDF)
Figure S2 Ex vivo images of abdominal aortas. After
removal of adventitia, aortas were pinned for photography. Ex
vivo diameters were measured using ImagePro Plus software.
These selected images represent outer diameters of suprarenal
aortas near the mean value of each group.
(PDF)
Figure S3 Pathology of abdominal aortic aneurysms.
Suprarenal aortas were sectioned and stained to determine tissue
characteristics. Movat’s pentachrome staining was performed to
visualize structures of aortic tissues. The images of representative
sections demonstrate the similar heterogeneity of aneurysmal
tissue pathologies in mice infused with PD123319 irrespective of
the AT2 genotype.
(PDF)
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